Articles On Pharmaust (ASX:PAA)

PharmAust will get early access to its FY22 R&D Tax Incentive amount, estimated at ~$210k, strengthening its financial position to execute on upcoming clinical trials. Clinical stage biotech PharmAust (ASX:PAA) has received a portion of...

PharmAust (ASX:PAA) has announced the arrival of its cGMP grade monepantel tablets specifically designed for the MND trial in Melbourne.

PharmAust (ASX: PAA) is on track to start a clinical trial of its monepantel (MPL) drug in motor neurone disease (MND) this month following the delivery of tablets to its trial site in Melbourne. The clinical-stage biotechnology company tod...

The much anticipated Phase 1 clinical trial of PharmAust’s lead asset Monepantel on patients with Motor Neurone Disease (MND) is about to commence. Clinical stage biotech PharmAust (ASX:PAA) is ready to proceed to the all-important Phase 1...

PharmAust (PAA) receives its first monepantel (MPL) tablets specifically designed for the Phase I motor neuron disease (MND) trial in Melbourne The current Good Manufacturing Practice (cGMP) grade MPL tablets are designed with a different...

The ASX 200 is set to open higher today, extending Friday’s 2% gain US Fed Chairman Jerome Powell has ruled out a 75bp hike for now eToro’s analyst Josh Gilbert is still optimistic about the current market ASX to extend Friday’s gain as W...

PharmAust (ASX:PAA) has announced an agreement with Pathway Vet Alliance dba as Thrive Pet Healthcare and Heart of Texas Veterinary Specialty Centre in the US to join the monepantel pet dog B cell lymphoma trial.

The expansion of the canine trial of Monepantel to the US comes after successful earlier trials in both Australia and New Zealand.  Clinical stage biotech PharmAust (ASX:PAA) will expand its Monepantel (MPL) B-cell lymphoma canine trial to...

PharmAust’s (ASX: PAA) phase 2 trial evaluating its monepantel (MPL) drug in canines with B cell lymphoma has now expanded to the United States. The expansion comes after an agreement with Pathway Vet Alliance as Thrive Pet Healthcare and H...

PharmAust (PAA) expands its Monepantel B Cell Lymphoma canine trial into the US The biotech company penned a deal to include the Heart of Texas Veterinary Specialty Centre in the trial and will send tablets to the centre to treat up to ten...

Quarterlies: A data dump of intrigue and a smidgen of smoke and mirrors. But while the pain is akin to meeting your boyfriend’s parents, it always reveals a hell of a lot about the boy, inside the man. And so, Stockhead’s sublimely single b...

PharmAust (ASX: PAA) has announced the company is adequately funded to continue its current activities after releasing its March quarter (Q3 FY22) report this week. The Perth-based clinical stage biotechnology company completed the manufact...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Clinical stage biotechnology company PharmAust (ASX: PAA) has received a $708,000 research and tax development (R&D) tax refund for work undertaken by its wholly-owned subsidiaries Epichem and Pitney Pharmaceuticals. The Australian Tax...

The R&D refund provides PAA with timely cash support as it advances its exciting clinical trial pathway. Clinical stage biotech PharmAust (ASX:PAA) continued its run of positive news flow this morning, with confirmation of a federal R&a...

PharmAust (PAA) receives a $708,000 research and development tax incentive refund The company says the Australian Taxation Office (ATO) has recognised the research and development innovation of the clinical-stage biotechnology company’s wh...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

The much anticipated Phase 1 clinical trial of PharmAust’s lead asset monepantel on patients with Motor Neurone Disease (MND) will finally commence. Clinical stage biotech PharmAust (ASX:PAA) is set to commence the Phase I clinical trial fo...

Clinical-stage biotechnology company PharmAust (PAA) receives over $201,000 under the first instalment payment from FightMND for its Phase 1 motor neuron disease trial The company has received more than $881,000 to examine the effects of m...

Clinical-stage biotech PharmAust (ASX: PAA) is closer to starting its phase 1 clinical trial evaluating its monepantel (MPL) drug in motor neuron disease (MND) after receiving its first instalment of a funding commitment and appointing Alit...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

PharmAust says there’s a goldmine of unexplored data from companion animals’ cancer research –  data which could unlock answers to the nature of our own struggles with cancer. Cancer, it turns out, is the leading cause of death in companion...

The recent super-toppy prices of Australia’s major commodity exports took a rare backward step today as analysts began to count the cost of China’s latest no-Covid lockdowns. The mega-miners and most of the energy names dragged heavily on T...

The production of its own monepantel (MPL) drug means that PharmAust is now ready to commence human clinical trials of the drugs. Clinical stage biotech PharmAust (ASX:PAA) announced that it has shipped the first cGMP grade monepantel (MPL)...

PharmAust (PAA) completes manufacturing of current good manufacturing practice (cGMP) grade drug monepantel (MPL) With manufacturing completed, the product has been shipped to the US and tableting has commenced in San Diego The company say...

ASX to fall, Nasdaq shaves another 2% Wall Street was mainly lower overnight, as the tech heavy Nasdaq index slipped another 2% following its 2% fall on Friday. The S&P 500 index also closed lower by 0.74%, while the Dow finished flat....

Australian clinical-stage biotechnology company PharmAust (ASX: PAA) has commenced the manufacture of monepantel tablets to enable clinical trials into motor neurone disease and coronavirus. The company shipped the cGMP-grade (current Good...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

PharmAust (ASX:PAA) has provided an update on the Walter and Eliza Hall Institute investigation of the anti-viral effects of its monepantel upon human T-cell Leukaemia Virus -1 in vitro.

The WEHI study demonstrated that PharmAust’s lead drug monepantel can kill the HTLV-1 virus and inhibit its protein production. Clinical stage biotech PharmAust (ASX:PAA) has just announced preliminary results from its investigation into th...

Biotech PharmAust (ASX: PAA) has demonstrated its lead drug monepantel (MPL) can kill the leukaemia virus, while also having an anti-cancer effect, during pre-clinical research. The Walter and Eliza Hall Institute is investigating the antiv...

PharmAust (PAA) receives evidence its monepantel (MPL) drug may inhibit the human T-cell leukaemia virus (HTLV-1) The results are from in vitro assays under an investigation by the Walter and Eliza Hall Institute The drug may inhibit the v...

PharmAust’s appointment of UK-based Ergomed means that it’s now in a position to start on the COVID-19 clinical trial of monepantel in the coming months. Clinical stage biotech PharmAust (ASX:PAA) has broken new ground on the planned clinic...

Clinical-stage biotechnology company PharmAust (ASX: PAA) has engaged UK-based Ergomed Clinical Research to commence clinical trials into the anti-viral effects of lead drug monepantel (MPL) in patients infected with SARS-CoV2, the causativ...

PharmAust (PAA) has appointed Ergomed Clinical Research to commence COVID-19 clinical trials The trials are testing the anti-viral effects of monepantel (MPL) in individuals infected with COVID-19 Ergomed has already found seven hospitals...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX 200 Health Index (XHJ) is up by over 4%, while the benchmark ASX 200 is rising by 0.5%. Blood products giant CSL (ASX:CSL) delivered a 5% jump in revenue for the first half, but its net profit slid by 5%. Rev...

Epichem’s successful e-waste project could create new revenue streams for PharmAust, as it eyes the lucrative waste and mining industry. PharmAust (ASX:PAA)’s goal of building a technology to convert waste to valuable assets has taken a maj...

PharmAust’s (PAA) subsidiary successfully completed the Oxidative Hydrothermal Dissolution (OHD) technology project from a $200,000 grant It yielded promising results prompting subsidiary, Epichem, to continue to advance the research and d...

The S&P/ASX200 pared earlier losses to finish ~0.2% lower. Wall Street lifted, but my word  — those gains were undermined by an after market bombshell from Facebook’s weird parent company, Meta ($FB), which slumped after totally disresp...

PharmAust (PAA) announces manufacturing for monepantel is on track to meet the nominated clinical trial deadlines Manufacturing of the drug is scheduled for completion this month with tableting expected next month The company said implemen...

PharmAust is passing all the tests and is on schedule to start its crucial Phase I/II trial of monepantel in patients with Motor Neurone Disease, offering hope to suffers. In an update on manufacture of tablets for its human trials, clinic...

PharmAust’s clinical trials of monepantel in dog cancer, COVID-19 and motor neurone disease are all expected to start in May 2022, with human cancer anticipated to commence Q4 CY 2022. Clinical stage biotech PharmAust (ASX:PAA) has provided...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

The renewal contract marks the 14th year of collaboration between PharmAust’s subsidiary Epichem and global non-profit organisation, DNDi. Clinical stage biotech, PharmAust (ASX:PAA), announced that its wholly-owned subsidiary Epichem has b...

PharmAust’s clinical trials of monepantel in canines, COVID-19 and motor neurone disease are all expected to start in May 2022, with human cancer anticipated to commence Q3/4 CY 2022.  Clinical stage biotech, PharmAust (ASX:PAA), has been b...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

PharmAust’s (PAA) upcoming human trials receives a major boost as the company’s GMP monepantel (MPL) tablets has been produced at a smaller size A total of 2000 smaller tablets were successfully produced using the same process as the large...